DNDi sponsored a HAT Symposium: “Addressing R&D challenges in making new drugs available for HAT: potential in the pipeline and recent clinical results”, including presentations on HAT platform, NECT, fexinidazole, and DB289.
DNDi also co-chaired a Malaria Symposium with sanofi-aventis.
Agenda
- If you would like to download the full HAT Symposium with the HAT Platform’s full Agenda, please click here.
- Malaria Symposium with sanofi-aventis
DNDi co-chaired a sanofi-aventis Symposium on “From field experience to the discovery of anti malarials: partnerships
in action” where the ASAQ field monitoring plan was presented.
- Chair: Wilfred Mbacham, Biotechnologies Centre, University of Yaounde I, Yaounde, Cameroon.
1 Review of clinical experience with the artesunate-amodiaquine fixed-dose combination
by Milijaona Randrianarivelojosia
Institut Pasteur, Madagascar.
2 Efficacy and safety monitoring in the field: The artesunate-amodiaquine fixed-dose combination monitoring plan
by Francois Bompart
sanofi-aventis Access to Medicines, Paris, France.
3 New approaches for the treatment of severe malaria: bis-thiazolium SAR97276
by Henri Vial
University Montpellier, Montpellier, France.
4 The search for new antimalarial drugs: Sanofi- Aventis’ R and D program
by Laurent Fraisse
sanofi-aventis, Toulouse, France.
Presentations
- HAT Symposium with the HAT Platform
- Chairs: Leon Kazumba, HAT Platform, Kinshasa, DRC, & Pere Simarro, WHO, Geneva, Switzerland
1 HAT Platform – Success to date, and challenges/opportunities ahead in overcoming difficulties in clinical research of HAT
drugs & in developing regional research platform
by Fred Kansiime, HAT Platform, Coordination Office for Control of Trypanosomiasis in Uganda, Kampala, Uganda
.
2 Phase III results of multi-center study evaluating nifurtimox-eflorthine combination for treatment (NECT) of Stage 2 HAT
by Elisabeth Baudin, on behalf of Gerardo Priotto, Epicentre, Paris, France
.
3 Research results evaluating the diamidine class for the treatment of HAT
by Carol Olson, Immtech Pharmaceuticals, Vernon Hills, IL, USA.
4 Fexinidazole: a rediscovered nitroimidazole drug candidate moving into clinical development for HAT
by Els Torreele, Drugs for Neglected Diseases initiative, Geneva, Switzerland
.
Interventions by Christian Burri, Swiss Tropical Institute, Basel, Switzerland, and Constantin Miaka Mia Bilenge, HAT National Control Program, Kinshasa, Democratic Republic of the Congo (DRC), followed by a Q&A session.
- Malaria Symposium with sanofi-aventis
- Chair: Wilfred Mbacham, Biotechnologies Centre, University of Yaounde I, Yaounde, Cameroon.
1 Review of clinical experience with the artesunate-amodiaquine fixed-dose combination
by Milijaona Randrianarivelojosia
Institut Pasteur, Madagascar, Madagascar.
2 Efficacy and safety monitoring in the field: The artesunate-amodiaquine fixed-dose combination monitoring plan
by Francois Bompart
sanofi-aventis Access to Medicines, Paris, France.
3 New approaches for the treatment of severe malaria: bis-thiazolium SAR97276
by Henri Vial
University Montpellier, Montpellier, France.
4 The search for new antimalarial drugs: Sanofi- Aventis’ R and D program
by Laurent Fraisse
sanofi-aventis, Toulouse, France.
- Additional partner presentations
DNDi was also pleased to have a number of other presentations made by project partners. These included the following:
– ASMQ intervention study
– ASMQ age- and weight-based dosing
– Anacor
– Scynexis
Press Releases
- If you would like to read the HAT Symposium with the HAT Platform’s Press Release, please click here.
Science.com Article
- If you would like to read the Science.com’s Press Article, please click here.
Videos
DNDi facilitated 3 Video sessions on “Survival – the Deadliest Diseases”
- If you would like to see the 57th ASMTH’s flyer, please click here.
